272
Participants
Start Date
September 23, 2020
Primary Completion Date
January 20, 2025
Study Completion Date
January 20, 2025
Aplitabart (IGM-8444)
DR5 Agonist Investigational Drug
FOLFIRI
Chemotherapy Regimen
Bevacizumab (and approved biosimilars)
Targeted Therapy
Birinapant
SMAC-mimetic Investigational Drug
Venetoclax
Targeted Therapy
Gemcitabine
Chemotherapy
Docetaxel
Chemotherapy
Azacitidine
Chemotherapy
Westmead, Westmead
Southern Medical Day Care Centre, Wollongong
Napean Cancer Care, Kingswood
Peter MacCallum Cancer Centre, Melbourne
Queen Elizabeth Hospital, Woodville South
Gachon University Gil Hospital, Gyeonggi-do
Seoul National University Bundang Hospital, Gyeonggi-do
Centre Georges Francois Leclerc, Dijon
Maryland Oncology Hematology, PA - Columbia, Columbia
Inova Schar Cancer Institute, Fairfax
Virginia Cancer Specialists, Fairfax
US Oncology- Virginia Oncology - Norfolk, Norfolk
Clinica Universidad de Navarra, Madrid
Madrid FJD, Madrid
Madrid CIOCC - HM Universitario Sanchinnarro, Madrid
Mayo Clinic, Jacksonville
FL Cancer Specialists - Lake Mary, Lake Mary
Memorial Cancer Institute, Pembroke Pines
Institut Bergonié, Bordeaux
Florida Cancer Specialists, Sarasota
SCRI - Tennessee, Nashville
Norton Cancer Institute, Louisville
Gabrail Cancer Research, Canton
Institut de Cancérologie de l'Ouest, Saint-Herblain
Fort Wayne Medical Oncology and Hematology, Fort Wayne
START Midwest, Grand Rapids
Minnesota Oncology - Minneapolis Clinic, Minneapolis
Mayo Clinic, Minneapolis
Washington University School of Medicine, St Louis
Ochsner Cancer, Jefferson
Stephenson Cancer Center, Oklahoma City
Saint Louis Hospital, Paris
Mary Crowley Cancer Research, Dallas
US Oncology - Dallas, Dallas
Texas Oncology - Tyler, Tyler
US Oncology- Texas Oncology - Fort Worth, Fort Worth
The University of Texas, MD Anderson, Houston
Texas Oncology - San Antonio Northeast, San Antonio
Texas Oncology - Austin, Austin
Rocky Mountain Cancer Centers, Denver
SCRI at Healthone, Denver
Mayo Clinic, Phoenix
USC Norris, Los Angeles
UCLA, Los Angeles
Cancer and Blood Specialty Clinic (CBSC), Los Alamitos
City of Hope Comprehensive Cancer Center, Duarte
UC Irvine Manchester Pavilion, Orange
UCSF, San Francisco
Gustave Roussy, Villejuif
Providence Portland Medical Center, Portland
Seattle Cancer Alliance - Fred Hutch, Seattle
Yale Cancer Center, New Haven
Tasman Health, Southport
Samsung Medical Center, Seoul
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital - Yonsei Cancer Center, Soeul
Vall d'Hebron Institut d'Oncologia, Barcelona
Lead Sponsor
IGM Biosciences, Inc.
INDUSTRY